Contact us

Support


Home > Investment tools > They choose Russia > Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals

Endogenics LLC of Russia and China will build its integrated insulin plant in the Tula Region.

"The planned cost to construct our plant for production of all ready pharmaceutical forms of insulin would be USD 140MM. The plant capacity would be circa 20MM of insulin cartridges p.a. We plan creating 200 jobs 50% whereof are highly-qualified", TASS correspondents were informed by the corporate PR function citing Mr. Lev Grigoriev, Endogenics CEO.

01 September 2016
TASS
Investor
140.0 mln
Tula Region

Investor profile

Gan & Lee Pharmaceuticals

China

Company's website: http://www.ganlee.com/en/

T: +86 (10) 80593628

Private company

E-mail: info@ganlee.com

Contact: Mr. Gan Zhongru, President and CEO

Chinese Biotech  Major

Subscribe to Newsletters

Email: